Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients
Authors
Keywords
-
Journal
OncoImmunology
Volume 2, Issue 2, Pages e23079
Publisher
Informa UK Limited
Online
2013-01-24
DOI
10.4161/onci.23079
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-2
- (2014) G. Mignot et al. JOURNAL OF IMMUNOLOGY
- Trans-Presentation of IL-15 Dictates IFN-Producing Killer Dendritic Cells Effector Functions
- (2014) E. Ullrich et al. JOURNAL OF IMMUNOLOGY
- Exploiting antitumor immunity to overcome relapse and improve remission duration
- (2011) Lei L. Chen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
- (2011) Nicolas F Delahaye et al. NATURE MEDICINE
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
- (2011) Vinod P Balachandran et al. NATURE MEDICINE
- Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib
- (2010) Joan Maurel et al. CANCER
- Interleukin-2 treatment effect on imatinib pharmacokinetic, P-gp and BCRP expression in mice
- (2009) Benoît Hosten et al. ANTI-CANCER DRUGS
- The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC
- (2009) NJ Liptrott et al. BRITISH JOURNAL OF PHARMACOLOGY
- Natural Killer Cell IFN- Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients
- (2009) C. Menard et al. CANCER RESEARCH
- Phase II Trial of Docetaxal Plus Imatinib Mesylate in the Treatment of Patients With Metastatic Breast Cancer
- (2009) Denise A. Yardley et al. Clinical Breast Cancer
- Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders
- (2009) N. Singh et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
- (2009) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
- (2008) R. A. Larson et al. BLOOD
- Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis
- (2008) Daniela Matei et al. CANCER
- Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
- (2008) Michael C. Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now